Cargando…

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

The basic leucine zipper transcription factor CCAAT/enhancer binding protein alpha (CEBPA) codes for a critical regulator during neutrophil differentiation. Aberrant expression or function of this protein contributes to the development of acute myeloid leukemia (AML). In this study, we identified tw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Federzoni, Elena A., Humbert, Magali, Torbett, Bruce E., Behre, Gerhard, Fey, Martin F., Tschan, Mario P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939455/ https://www.ncbi.nlm.nih.gov/pubmed/24584857 http://dx.doi.org/10.1038/srep04261

Ejemplares similares

Linking the SUMO protease SENP5 to neutrophil differentiation of AML cells
por: Federzoni, Elena A., et al.
Publicado: (2015)

Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy
por: Jin, Jing, et al.
Publicado: (2018)

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
por: Pabst, T, et al.
Publicado: (2009)

Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’
por: Hou, H-A, et al.
Publicado: (2009)

Long-term follow-up of cytogenetically normal CEBPA-mutated AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
por: Jakobsen, Janus S., et al.
Publicado: (2019)

The autophagy scaffold protein ALFY is critical for the granulocytic differentiation of AML cells
por: Schläfli, Anna M., et al.
Publicado: (2017)

The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML
por: Eyholzer, M, et al.
Publicado: (2010)

BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation
por: Schläfli, Anna M, et al.
Publicado: (2012)

PB1768: MICRORNA SIGNATURES IMPLY A ROLE FOR FOXO IN AML CHEMO-RESISTANCE
por: Reichelt, Paula, et al.
Publicado: (2023)

Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases
por: Fasan, Annette, et al.
Publicado: (2013)

The ATRA-21 gene-expression model predicts retinoid sensitivity in CEBPA double mutant, t(8;21) and inv(16) AML patients
por: Bolis, Marco, et al.
Publicado: (2019)

MicroRNA Expression Patterns Reveal a Role of the TGF-β Family Signaling in AML Chemo-Resistance
por: Reichelt, Paula, et al.
Publicado: (2023)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
por: Salmon, Jessica M., et al.
Publicado: (2022)

Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML
por: Islam, Mirazul, et al.
Publicado: (2017)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

Targeting glutamine uptake in AML
por: Jacque, Nathalie, et al.
Publicado: (2014)

AML treatment in older adults
por: Sehgal, Alison, et al.
Publicado: (2015)

Impact of CNA on AML prognosis
por: Gonzales, Fanny, et al.
Publicado: (2017)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

Von AML bis Zytokinfreisetzung
por: Klein, Friederike
Publicado: (2022)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2023)

CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition
por: Liu, Meng, et al.
Publicado: (2022)

De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2017)

Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML
por: Mu, Guangfu, et al.
Publicado: (2020)

IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells
por: Liss, Franziska, et al.
Publicado: (2021)

STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML
por: Oancea, Claudia, et al.
Publicado: (2014)

Initiation of MLL-rearranged AML is dependent on C/EBPα
por: Ohlsson, Ewa, et al.
Publicado: (2014)

Securinine, a Myeloid Differentiation Agent with Therapeutic Potential for AML
por: Gupta, Kalpana, et al.
Publicado: (2011)

Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions
por: Seiler, Kristina, et al.
Publicado: (2022)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hr01qdtsen9ba2nvg9kvlrnp58